The real disruption isn’t lower prices—it’s visible margins Pharmaceutical executives have spent the better part of two decades preparing for […]

Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never

The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition

The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition

How inhalers, injectables, and drug-device combinations are reshaping generic drug strategy — and what it takes to win. Abbreviated New

Track drug development pipelines and patent filings to surface passive candidates six to eighteen months before your competitors do. When

How drug companies, insurers, payers, and patients absorb billions in collateral damage that never appears on a litigation docket “The

The Number Everyone Gets Wrong Twenty years. Ask any pharma executive or patent attorney how long a drug patent lasts

The Mechanism Most Analysts Still Underestimate Every few years, a drug that has been off-patent for a decade reappears in